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HIV Stigma Among Substance Abusing People Living
with HIV/AIDS: Implications for HIV Treatment
Maria A. Levi-Minzi, MA, and Hilary L. Surratt, PhD
Abstract
HIV-related stigma has a major impact on quality of life and health among people living with HIV and AIDS
(PLWHA). This study examines demographic, mental health, behavioral, contextual, and HIV care-related cor-
relates of HIV stigma among 503 substance abusing PLWHA. Stigma was measured with the HIV Internalized
Stigma Measure which has four subscales: stereotypes about HIV, self-acceptance, disclosure concerns, and social
relationships. Severe substance dependence (55.3%) and depression (54.7%) were associated with higher HIV
stigma across all domains. 49.9% of the sample reported antiretroviral (ARV) medication diversion (the unlawful
sale and trading of ARV medications); diverters endorsed significantly higher stigma related to disclosure. 54.1%
of the sample reported ‡ 95% ARV adherence; these individuals reported significantly lower stigma for self-
acceptance, disclosure, and social relationships. Multivariate linear regression showed that depression and social
support demonstrated significant main effects across stigma domains. Findings suggest that interventions to
decrease HIV related stigma may be an important component of initiatives to increase engagement in HIV care.
Introduction
Stigma is a complex social process encompassing theco-occurrence of labeling, stereotyping, separation, status
loss, and discrimination.1 Research has indicated that stigma
has a major impact on quality of life and overall health out-
comes among people living with HIV/AIDS (PLWHA).2,3
HIV-related stigma is often experienced as social rejection,
disapproval, and discrimination, which heightens shame and
fear of disclosure. Concealment of HIV + status can lead to
decreased social support, depression, inability to work, fi-
nancial strain, and the decision to forgo valuable medical
treatment.4–7 Higher levels of HIV-related stigma are asso-
ciated with: decreased antiretroviral medication adher-
ence and uptake of medical care; increased mental distress
including depression, anxiety, and hopelessness; and HIV-
related symptoms,2,6,8–12 making it difficult for PLWHA to
receive the optimal benefits of HIV care and treatment.13
HIV-related stigma has been described as encompassing
specific domains including internalized stigma (negative
feelings and beliefs associated with HIV and applied to the
self ), enacted stigma (actual experiences of discrimination,
stereotyping, and/or prejudice from others due to one’s HIV),
and anticipated stigma (expectations of discrimination, ste-
reotyping and/or prejudice from others in the future due to
one’s HIV);14 each of these has been associated with harms to
health and well-being, including under-utilization of HIV-
related medical care.15 In particular, internalized HIV stigma
has been linked to numerous adverse health and social con-
sequences for PLWHA including poor mental and physical
health status, as well as decreased social support, social in-
tegration and overall quality of life.11–13,16,17
Internalized HIV stigma incorporates four dimensions:
confronting blame and stereotypes of HIV; managing disclo-
sure of a stigmatized status; renegotiating social relationships;
and self-acceptance, or level of personal comfort with one’s
HIV diagnosis.2,16 Despite the potential significance of stigma
in the lives of many PLWHA, much of the research in this area
has been concentrated among injection drug users and men who
have sex with men, with some limited attention to ethnic
community, gender, or age-related analyses.13,18–20 Little is
known about how HIV stigma may impact other understudied
PLWHA, particularly those with intersecting stigmas, includ-
ing the indigent, non-IDU substance abusers, and PLWHA with
high levels of competing needs. Numerous studies have de-
scribed HIV-related stigma as multi-layered, encompassing
stigma related to HIV, as well as stigma based on a marginal-
ized group status such as age, race, socioeconomic status, or
sexual orientation, and other individualized factors including
substance abuse.2,13,18 The presence of multiple stigmas among
highly vulnerable PLWHA may be associated with an even
greater magnitude of effect on health-seeking behaviors, but
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this has not been well examined in prior research. The purpose
of this article is to examine the demographic, mental health,
behavioral, contextual, and HIV care-related correlates of
specific internalized HIV stigma domains among a sample of
socioeconomically disadvantaged substance abusing PLWHA,
in order to identify potential intervention targets to increase
uptake of care and ARV adherence. The present study was
guided by Andersen’s Behavioral Model for Vulnerable Po-
pulations, a conceptual model used to explore how predispos-
ing, enabling, and need factors predict personal health practices
and their relation to physical health and satisfaction with care
outcomes.21 For the purpose of this article, we sought to ex-
amine the predisposing factors of HIV-related stigma among a
vulnerable, indigent sample of PLWHA10 in an effort to un-
derstand how these they may influence HIV-related health
behaviors and care utilization.
Methods
Target population and study eligibility
The data were drawn from a mixed methods study designed
to examine the patterns and predictors of ARV diversion (the
unlawful sale and trading of ARV medications) among indigent
HIV-positive substance abusing individuals living within South
Florida. Eligible participants were those who: could provide
documentation of their HIV status and were currently prescribed
ARV medications; were age 18 or older; and reported cocaine,
crack, or heroin use 12 or more times in the past 90 days. The
additional criterion of diverter was satisfied by endorsement of
ARV medication diversion at least once in the past 90 days. We
sought to enroll equal numbers of users diverting their personal
ARV medications (n = 251) and those who were not (n = 252).
Study recruitment
In an effort to recruit this hard-to-reach population, we used
targeted sampling strategies, a purposeful, systematic sampling
method by which specified populations within geographical
districts are identified, and plans are constructed to recruit
specified numbers of individuals within each of the target
areas.22 Using existing data from the Miami Dade County
Department of Health and the US Census Bureau, we identified
communities most impacted by intersecting poverty and high
HIV prevalence, specifically geographically clustered con-
centrated poverty areas to the north of downtown.23–27
Primary recruitment was done through direct outreach and
was conducted through the distribution of study cards and flyers
in street venues and HIV service locations. Professional out-
reach workers, indigenous to the target recruitment areas, and
several members of the team had prior experience conducting
outreach for local community service agencies. Outreach teams
recruited from different sections the target areas on an at least
weekly basis over the 3-year study recruitment period. Key
informants such as street drug users, and community outreach
workers were also utilized in an effort to locate less visible
ARV diversion street market locations (e.g., small pharmacies
or other local hangouts) within the target areas.
Study procedures
Eligible participants were scheduled for appointments at
the project office following a brief telephone screening. 2112
individuals were screened, 599 met study eligibility criteria,
and 503 were enrolled into the study. The primary reason for
non-enrollment (84%) was repeated lack of attendance to the
scheduled interview. Upon arrival, participants were re-
screened, informed consent was obtained, and the trained
study staff conducted computer-assisted personal interviews
(CAPI). This interview typically lasted 1 h and clients were
paid a $30 stipend upon completion; each client was also
offered a variety of educational and risk reduction materials.
All project staff completed the requirements for National
Institutes of Health (NIH) web-based certification for pro-
tection of human subjects and a Certificate of Confidentiality
from the National Institutes of Health (NIH) was also ob-
tained. Study protocols were approved by the University of
Delaware’s (predecessor institution) and Nova Southeastern
University’s Institutional Review Boards.
Data collection and measures
Depending upon preference, interviews were offered to re-
spondents in both English and Spanish. The Global Appraisal
of Individual Needs (GAIN, v. 5.4)28 was the primary data
collection instrument for the survey study. Psychometric
studies have found Cronbach’s alphas between 0.9 and 0.8, and
behavior questions have demonstrated test-retest correlations
over 0.8.29 The GAIN has eight core sections encompassing:
demographics; mental health status, including DSM-IV de-
pression, anxiety measures, and substance use and DSM-IV
dependence; HIV risk behaviors; and environmental, legal, and
vocational measures. Other standardized instruments were also
used to measure HIV diagnosis/treatment history,30 ARV ad-
herence,31 attitudes toward HIV providers,32 and ARV medi-
cations, health literacy and HIV knowledge, and HIV treatment
satisfaction and access.33 A new instrument was also developed
to assess ARV medication diversion.
Demographic information including age, race, gender, level
of education, and monthly income were collected. HIV stigma,
the main outcome variable for this analysis, was assessed
through a modified version of the HIV Internalized Stigma
Measure,16 which contained 11 items; this was an adaptation of
the original scale based on item appropriateness for the target
population and elimination of duplicative items from other
measures. Overall and stigma scores were calculated as a sum of
these 11 items; scores ranging from 11 to 44, with higher scores
reflecting greater levels of stigma. Our adapted measure in-
cluded all four subscales: stereotypes about HIV (three items,
scores range from 3 to 12; a= 0.720), self-acceptance (three
items, scores range from 3 to 12, a = 0.688), disclosure concerns
(two items scores range from 2 to 8; a = 0.718), and social
relationships (three items, scores range from 3 to 12; a = 0.828).
Participants were retained on the subscales where they had
complete data, and those with missing values were not included.
Mental health factors. These were collected from the
GAIN’s mental health subscales (based on DSM-IVR crite-
ria): the depressive symptom scale assesses past 12 month
occurrence of nine depressive symptoms (e.g., feeling sad,
lonely, or hopeless; feeling tired or having no energy) and is
scored as none/minimal (0–1), moderate (2–5), or severe (6–9);
and past year substance dependence, encompassing questions
related to past year drug problem severity (e.g., using more
or longer than intended, withdrawal problems) was mea-
sured through seven items, with endorsement of six or more
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showing severe dependence. Alpha reliability coefficients for
these scales are as follows: depression (a = 0.77) and sub-
stance dependence (a = 0.83).28
Behavioral factors. To assess ARV diversion, partici-
pants were asked: ‘‘When was the last time, if ever, that you
sold or traded any of your HIV medications to another person
for any reason?’’ This variable was dichotomized into
‘‘within the past 3 months’’ or ‘‘more than 3 months ago.’’
Medication adherence was assessed via the ACTG Ques-
tionnaire.31 The ARV section gathered total ARV doses
prescribed and total doses in the past 7 days. Using these data,
weekly ARV doses taken were computed and divided by total
doses prescribed to generate an adherence percentile score.
Contextual factors. As suggested by Earnshaw and Ka-
lichman,13 there are unique interpersonal drivers of HIV
stigma within the sociocultural context of each individual. In
this regard, individual contextual factors of our participants
encompassed aspects related to housing, length of time since
HIV diagnosis, and levels of social support. Recent home-
lessness was also assessed through the question, ‘‘When was
the last time you considered yourself to be homeless?’’ This
variable was dichotomized for analysis into ‘‘within the past
3 months’’ or ‘‘more than 3 months ago.’’
Participant response (month and year) were recorded when
asked ‘‘When were you first diagnosed with HIV infection?’’
and a variable was created to calculate the number of years
with HIV by subtracting the year of diagnosis from the in-
terview year. Length of time on ARVs was assessed in a
similar way; participant response (month and year) were re-
corded for the question ‘‘When were you first prescribed to
take any HIV medications?’’ Subsequently, a variable was
created to calculate the number of years on ARVs by sub-
tracting the year of first ARV prescription from the interview
year. This measure provides an estimate of time on ARVs,
but we were unable to assess whether ARV medication use
was continuous during the documented time period.
General social support was assessed via the following three
items adapted from the HIV Health Care Cost and Services
Utilization Study:34 Someone to give you money if you really
need it; someone to help with chores, errands, or appoint-
ments if you were sick; and someone to love you and make
you feel wanted; it is scored on a 1–5 scale (none of the time–
all of the time), with higher scores indicating more support.
The alpha reliability coefficient for our sample was a = 0.76.
HIV care-related factors. Care related factors were
measured via standardized scales. Patient attitudes toward
HIV providers in terms of professionalism and emotional
support were calculated through a revised version of the
Attitudes Toward HIV Health Care Providers Scale,32 a 12-
item instrument with answer choices ranging from 1 to 4
(strongly disagree–strongly agree); scores range from 12 to
48 and higher scores reflect more perceived support. The
alpha reliability coefficient for measure among our sample
was a = 0.87. The revised Antiretroviral Medication Attitude
Scale (AMAS) is a 15-item instrument (true/false response
choices) used to assess four dimensions of attitudes regarding
ARV medications: improvement, negative reminders of ill-
ness, flexibility and control over medications, and the ability
of ARV’s to prevent negative health consequences; the scale
has high internal consistency with a published Cronbach’s
alpha of 0.84;35 for our adapted version of this measure, the
alpha reliability coefficient a = 0.57.
HIV treatment access was calculated via the general access
to care questions from the HIV Health Care Cost and Services
Utilization Study,33 which includes seven items such as
‘‘Places where I can get medical care are very conveniently
located’’ and ‘‘I have easy access to the medical specialists I
need.’’ Responses were combined to calculate a treatment
access score; scores are on a 1–4 scale (strongly agree to
strongly disagree) and range from 7 to 28, with higher scores
indicating more ease in accessing treatment. Alpha reliability
coefficient for this scale among our sample was a = 0.81.
Statistical analysis
Data were analyzed using IBM SPSS Statistics, version 21 36.
Descriptive statistics were calculated to describe the sample in
terms of: demographics; mental health, including depression
and substance dependence; behavioral factors, including recent
(past 90 day) ARV diversion and adherence; contextual factors,
including number of years with a diagnosis of HIV, length of
time taking ARVs, and social support; and HIV care factors,
including attitudes toward providers and ARV medications and
treatment access. Mean overall stigma scale scores and mean
subscale scores (stereotypes about HIV, self-acceptance, dis-
closure concerns, and social relationships) were examined for
each variable of interest. For the purpose of means testing,
continuous variables, including number of years with a diag-
nosis of HIV, social support, attitudes toward providers and
ARV medications, and treatment access, were dichotomized
using a median split. T-tests were utilized to examine differ-
ences in demographic (age, gender, race, education), mental
health (depression and substance dependence), behavioral fac-
tors (recent ARV diversion and adherence), contextual factors
(time since HIV diagnosis and social support), and HIV care
factors (attitudes toward providers and ARV medications and
HIV treatment access) by each stigma subscale. Significance
level was set at p < 0.05 for all comparisons.
Four multivariate linear regression models were then con-
structed to examine the associations between the significant
independent variables (demographic, mental health, behav-
ioral, contextual, and HIV care factors) and each stigma
subscale score. For the regression analyses, internalized
stigma subscales were the outcomes of interest, with each
treated as a continuous variable; all independent variables
(race, depression, substance dependence, ARV diversion and
adherence, and homelessness, time since HIV diagnosis,
length of time taking ARVs, social support, treatment access,
attitude toward HIV providers, and ARV medications) in the
models were treated as dichotomous variables using the me-
dian cutpoints from the bivariate analyses. Multicollinearity
analyses were conducted for the independent variables of
interest and no evidence of multicollinearity was found after
examining the variance inflation factor (VIF < 3). Variables
were entered simultaneously into the linear regression model.
Results
Sample characteristics are displayed in Table 1. The mean
age of the sample was 46.07 (SD 7.77; range 19–71) and
more than half of the respondents were male (59.4%). The
sample was predominately African American (67.6%), with
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over half having less than a high school education (56.5%).
The majority of participants (81.1%) had a monthly income
of under $1000 and many reported elevated rates of mental
health problems.
Bivariate results
The overall mean stigma score for the sample was 23.87
(SD 7.65). In terms of race, as compared to African Ameri-
cans, all other races (predominately white and Hispanic)
experienced significantly higher stigma overall and specifi-
cally related to stereotypes (8.26 vs. 7.61, p < 0.05) and social
relationships (5.51 vs. 4.96, p < 0.05).
As indicated in Table I, subscale stigma scores were sig-
nificantly associated with several mental health, behavioral,
contextual, and HIV care-related factors. When examining
mental health factors, those with severe depression (54.7%)
reported significantly higher mean stigma scores overall
compared to those without severe depression and specifically
related to stereotypes (8.40 vs. 7.12, p < 0.01), self-acceptance
(7.57 vs. 6.52, p < 0.01) disclosure (4.43 vs. 3.28, p < 0.01),
and social relationships (5.91 vs. 4.21, p < 0.01). Participants
reporting severe substance dependence (55.3%) also en-
dorsed higher mean HIV stigma scores overall and related to
stereotypes (8.24 vs. 7.31, p < 0.01), self-acceptance (7.71 vs.
6.34, p < 0.01), disclosure (4.19 vs. 3.56, p < 0.01), and social
relationships (5.56 vs. 4.62, p < 0.01) compared with the non-
dependent.
Behavioral factors were also significantly associated with
HIV-related stigma. Nearly 50% of the sample reported re-
cent ARV diversion, with diverters endorsing significantly
higher stigma overall and related to disclosure (4.09 vs. 3.73,
p < 0.05) compared with non-diverters; 54.1% of the sample
reported 95% ARV adherence, with these individuals re-
porting significantly lower stigma overall and in relation to
self-acceptance (6.82 for adherent vs. 7.42 for nonadherent,
p < 0.05), disclosure (3.74 vs. 4.10, p < 0.05), and social re-
lationships (4.93 vs. 5.39, p < 0.05) when compared to those
with less than 95% adherence.
In terms of contextual factors, participants reporting re-
cent homelessness had higher stigma overall and related to
stereotypes (8.55 vs. 7.36, p < 0.01), self acceptance (7.54 vs.
Table 2. Multivariate Linear Regression Model Predicting Stigma Related
to Stereotypes Among HIV + Substance Abusers in South Florida, N = 494
Unstandardized B (SE) Standardized b 95% CI p Value
African Americana - 0.29 - 0.05 - 0.78, 0.20 0.24
Severe depressiona 0.62 0.12 0.011, 1.12 0.02
Severe substance dependencea 0.37 0.07 - 0.12, 0.86 0.14
Recent ARV diversiona 0.14 0.03 - 0.34, 0.62 0.57
95% ARV adherencea 0.28 0.05 - 0.19, 0.75 0.25
Recent (past 90 day) homelessnessa 0.68 0.12 0.19, 1.16 0.01
Diagnosed with HIV 13 years or more agob - 0.16 - 0.03 - 0.71, 0.39 0.56
Taking ARVs 10 years or morec - 0.09 - 0.02 - 0.65, 0.47 0.75
Higher social supportd - 0.98 - 0.18 - 1.45, - 0.51 0.00
Favorable attitude toward HIV providerse - 0.16 - 0.03 - 0.65, 0.33 0.53
Positive ARV medication attitudesf - 0.32 - 0.06 - 0.79, 0.16 0.19
More treatment accessg - 0.46 - 0.09 - 0.95, 0.04 0.07
aReference category is ‘no’; bReference category is ‘diagnosed 12 or less years ago’; cReference category is ‘taking ARV’s 9 years or
less’; dReference category is ‘lower social support’; eReference category is ‘less favorable attitude toward HIV providers’; fReference
category is ‘negative ARV medication attitudes’; gReference category is ‘less treatment access’.
Table 3. Multivariate Linear Regression Model Predicting Stigma Related to Disclosure
Concerns Among HIV + Substance Abusers in South Florida, N = 503
Unstandardized B (SE) Standardized b 95% CI p Value
African Americana 0.26 0.06 - 0.11, 0.62 0.17
Severe depressiona 0.75 0.18 0.37, 1.12 0.00
Severe substance dependencea 0.19 0.05 - 0.18, 0.55 0.31
Recent ARV diversiona - 0.01 - 0.00 - 0.37, 0.35 0.95
95% ARV adherencea - 0.14 - 0.04 - 0.50, 0.21 0.43
Recent (past 90 day) homelessnessa - 0.02 - 0.00 - 0.38, 0.35 0.43
Diagnosed with HIV 13 years or more agob - 0.10 - 0.02 - 0.51, 0.32 0.64
Taking ARVs 10 years or morec - 0.37 - 0.09 - 0.78, 0.05 0.09
Higher social supportd - 0.37 - 0.09 - 0.72, - 0.02 0.04
Favorable attitude toward HIV providerse - 0.38 - 0.09 - 0.75, - 0.01 0.05
Positive ARV medication attitudesf - 0.39 - 0.10 - 0.74, - 0.03 0.03
More treatment accessg - 0.67 - 0.16 - 1.04, - 0.29 0.00
aReference category is ‘no’; bReference category is ‘diagnosed 12 or less years ago’; cReference category is ‘taking ARV’s 9 years or
less’; dReference category is ‘lower social support’; eReference category is ‘less favorable attitude toward HIV providers’; fReference
category is ‘negative ARV medication attitudes’; gReference category is ‘less treatment access’.
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6.81, p < 0.05), disclosure (4.22 vs. 3.71, p < 0.05), and social
relationships (5.75 vs. 4.76, p < 0.01) than the non-homeless.
The mean number of years since HIV diagnosis was 12.94
(SD 5.34). Those with an HIV diagnosis for 13 years or more
had lower self-acceptance stigma (6.78 vs. 7.42, p < 0.01) and
disclosure stigma (3.73 vs. 4.11, p < 0.01). In terms of length
of time prescribed ARVs, the mean for the sample was 9.77
(SD 6.6), and taking ARVs for 10 years or more had signif-
icantly lower stigma related to self-acceptance (6.77 vs. 7.48,
p < 0.05) and disclosure concerns (4.22 vs. 3.64, p < 0.01).
Social support (mean 10.14, SD 3.25) was also related to HIV
stigma; higher social support indicated lower stigma for all
stigma subscales.
HIV care related factors were also associated with stigma.
More favorable attitudes toward HIV care providers were cor-
related with lower stigma overall and for stereotypes (7.44 vs.
8.24, p < 0.01), self-acceptance (6.64 vs. 7.60, p < 0.01), disclo-
sure (3.51 vs. 4.35, p < 0.01), and social relationships (4.44 vs.
5.93, p < 0.01). Similarly, participants with positive attitudes
toward ARV medications had decreased stigma overall and
related to stereotypes (7.41 vs. 8.28, p < 0.01), self-acceptance
(6.44 vs. 7.78, p < 0.01), disclosure (3.49 vs. 4.37, p < 0.01), and
social relationships (4.45 vs. 5.89, p < 0.01). More access to
treatment was associated with decreased stigma overall and
related to stereotypes (7.30 vs. 8.41, p < 0.01), self-acceptance
(6.44 vs. 7.83, p < 0.01), disclosure (3.38 vs. 4.50, p < 0.01), and
social relationships (4.52 vs. 5.86, p < 0.01).
Multivariate results
Tables 2 through 5 show the results of each multivariate
linear regression model examining the associations of race,
depression, substance dependence, ARV diversion and ad-
herence, recent homelessness, time since HIV diagnosis,
length of time taking ARVs, social support, attitudes toward
ARV medications and treatment providers, and treatment
access with each stigma domain. Depression, recent home-
lessness, and higher social support demonstrated significant
main effects on stigma related to stereotypes: depression was
associated with higher stigma (b = 0.62, p = 0.02); recent
homelessness was also associated with increased stigma
(b = 0.68, p = 0.01), whereas higher social support yielded
Table 4. Multivariate Linear Regression Model Predicting Stigma Related
to Self-Acceptance Among HIV + Substance Abusers in South Florida, N = 492
Unstandardized B (SE) Standardized b 95% CI p Value
African Americana 0.23 0.04 - 0.32, 0.76 0.42
Severe depressiona 0.09 0.01 - 0.47, 0.64 0.76
Severe substance dependencea 1.02 0.17 0.48, 1.56 0.00
Recent ARV diversiona - 0.24 - 0.04 - 0.77, 0.29 0.38
95% ARV adherencea - 0.37 - 0.06 - 0.89, 0.16 0.17
Recent (past 90 day) homelessnessa - 0.04 - 0.01 - 0.58, 0.49 0.87
Diagnosed with HIV more than 13 years or more agob - 0.30 - 0.05 - 0.90, 0.31 0.34
Taking ARVs 10 years or morec - 0.39 - 0.07 - 1.00, 0.23 0.22
Higher social supportd - 0.89 - 0.15 - 1.41, - 0.37 0.00
Favorable attitude toward HIV providerse - 0.28 - 0.05 - 0.82, 0.27 0.32
Positive ARV medication attitudesf - 0.80 - 0.14 - 1.33, - 0.28 0.00
More treatment accessg - 0.81 - 0.14 - 1.35, - 0.26 0.00
aReference category is ‘no’; bReference category is ‘diagnosed 12 or less years ago’; cReference category is ‘taking ARV’s 9 years or
less’; dReference category is ‘lower social support’; eReference category is ‘less favorable attitude toward HIV providers’; fReference
category is ‘negative ARV medication attitudes’; gReference category is ‘less treatment access’.
Table 5. Multivariate Linear Regression Model Predicting Stigma Related to Social
Relationships Among HIV + Substance Abusers in South Florida, N = 492
Unstandardized B (SE) Standardized b 95% CI p Value
African Americana - 0.07 - 0.01 - 0.51, 0.37 0.77
Severe depressiona 1.02 0.20 0.56, 1.47 0.00
Severe substance dependencea 0.21 0.04 - 0.23, 0.65 0.35
Recent ARV diversiona - 0.17 - 0.03 - 0.60, 0.26 0.43
95% ARV adherencea - 0.23 - 0.04 - 0.64, 0.21 0.31
Recent (past 90 day) homelessnessa 0.34 0.06 - 0.10, 0.77 0.13
Diagnosed with HIV 13 years or more agob 0.08 0.02 - 0.42, 0.57 0.76
Taking ARVs 10 years or morec 0.49 0.09 - 0.02, 0.99 0.06
Higher social supportd - 1.12 - 0.22 - 1.54, - 0.70 0.00
Favorable attitude toward HIV providerse - 0.75 - 0.15 - 1.19, - 0.31 0.00
Positive ARV medication attitudesf - 0.85 - 0.17 - 1.27, - 0.43 0.00
More treatment accessg - 0.41 - 0.08 - 0.86, 0.03 0.07
aReference category is ‘no’; bReference category is ‘diagnosed 12 or less years ago’; cReference category is ‘taking ARV’s 9 years or
less’; dReference category is ‘lower social support’; eReference category is ‘less favorable attitude toward HIV providers’; fReference
category is ‘negative ARV medication attitudes’; gReference category is ‘less treatment access’.
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lower stigma (b = - 0.98, p = 0.00). This regression model
had an adjusted R square of 0.13.
Depression was associated with significantly higher dis-
closure stigma (b = 0.75, p = 0.00); significant associations
showing lower stigma related to disclosure concerns included
more favorable attitudes toward HIV providers (b = - 0.38,
p = 0.05), ARV medications (b = - 0.39, p = 0.03), and better
treatment access (b = - 0.67, p = 0.00). This regression model
had an adjusted R square of 0.153.
In terms of self-acceptance stigma, substance dependence
was associated with significantly higher levels of stigma
(b = 1.02, p = 0.00); lower levels of stigma were associated
with higher social support (b = - 0.89, p = 0.00), more posi-
tive ARV medication attitudes (b = - 0.80, p = 0.00), and
better treatment access (b = - 0.81, p = 0.00). The adjusted R
square of this regression model was 0.139.
Depression was associated with higher stigma related to
social relationships (b = 1.02, p = 0.00) and lower levels of
stigma were linked to higher social support (b = - 1.12,
p = 0.00), more favorable attitudes toward HIV providers
(b = - 0.75, p = 0.00), and ARV medications (b = - 0.85,
p = 0.00). The adjusted R square for this model was 0.26.
Discussion
This study reports novel and significant findings on demo-
graphic, mental health, behavioral, contextual, and care-related
factors associated with internalized HIV stigma among a sam-
ple of indigent substance using seropositive individuals in South
Florida. Our data highlight the fact that mental health prob-
lems, including severe depression, were associated with
higher stigma related to stereotypes, disclosure, and social
relationships, indicating that individuals with psychological
distress may be less willing to obtain and take their ARV
medications due to fears related to disclosing their status.
This would appear to constitute a significant risk factor for
attending and remaining engaged in regular HIV care. Si-
milar to some prior research,37 substance dependence symp-
toms for our sample were tied to significantly higher stigma
overall and related to self-acceptance; these findings are
contrary to some studies which have found lower levels of
HIV stigma among substance abusers.19
Sayles and colleagues2 indicated that stereotypes related to
HIV often encompass feelings of blame for the infection
based on how it was acquired, and suggest that these feelings
are made more intense due to individuals self judgments and
feelings of shame around being HIV positive; blame for HIV
infection was also found to be further intensified by other
factors associated with marginalization, including race and
gender.2 Contrary to these findings, we did not find signifi-
cant differences in HIV related stigma based on gender.7,19
Moreover, despite previous research indicating that African
Americans experience higher levels of HIV related stigma,19
we found significantly higher stigma for other races as
compared to African Americans. We speculate that this
finding may reflect the disproportionately high rates of in-
fection that have impacted African American communities in
South Florida for many years,38 which may have led to
greater community acceptance; moreover it is possible that
the intense outreach efforts and services targeting these
communities have allowed for PLWHA to feel less stereo-
typed and more comfortable with their diagnosis.
Behavioral factors including ARV adherence and diver-
sion were also significantly tied to internalized stigma. Those
who were adhering to their ARV regimen had lower HIV
stigma related to stereotypes, disclosure, and social rela-
tionships, suggesting that the adherent experienced less dis-
tress related to their HIV status. These findings seem to
resonate with other recent studies of substance abusing
PLWHA, which have documented that differences in stress
tolerance (one’s ability or perceived capacity to tolerate
distress) and health care provider interest and satisfaction
also play an important role in ARV medication adher-
ence.39,40 In contrast, diverters had higher stigma related to
disclosure, indicating that perhaps the need or desire to conceal
HIV status could potentially play a role in the decision to divert
medications. Although these associations did not remain sig-
nificant in the multivariate analyses, these results may indicate
that decreases in stigma related to disclosure would be useful in
promoting adherence and reducing diversion among this highly
marginalized population of PLWHA, making this a potential
target for intervention. The contextual factor of time since di-
agnosis was also related to stigma. Those reporting a diagnosis
13 years ago or more had significantly lower levels of stigma
related to disclosure and self-acceptance. These results com-
plement numerous studies documenting that more recently
diagnosed individuals experience significantly higher levels of
HIV related stigma.5,10,11,19,20 Similarly, length of time taking
ARV medications was also significantly associated with lower
stigma related to self-acceptance and disclosure concerns.
Results from the multivariate analyses indicate that higher
levels of social support are associated with decreased stigma
related to stereotypes, self-acceptance, and social relation-
ships; these findings are consistent with other literature
showing that higher social support is associated with lower
levels of HIV stigma.20 The multivariate analyses also showed
self-acceptance to be associated with numerous factors; spe-
cifically, those reporting severe substance dependence had
higher levels stigma related to self acceptance; lower levels of
self-acceptance stigma were associated with higher social
support, more favorable ARV attitudes, and better treatment
access. Since provider satisfaction has been found to be asso-
ciated with ARV adherence in other substance abusing popu-
lations of PLWHA,40 our findings seem to highlight the
importance of interventions addressing stigma related to self
acceptance as targets to increase engagement and retention in
HIV care. Our results also help to illustrate the documented
relationship between self-acceptance stigma and social support;
self-acceptance has been found to serve as a first step in the
process of reintegrating and re-connecting with loved ones post
HIV diagnosis.2
Limitations
There are several limitations to this study. This sample,
although large, is not representative, given that recruitment
for the study was limited to substance using, indigent indi-
viduals in high poverty areas. Further, given the focus on
ARV diversion, it is likely that our sample is different from
other HIV-positive community based samples, making it
difficult to generalize our results. The study also relied on
self-report data, which is subject to reporting and social de-
sirability bias and recall problems; however, the high levels
of mental health problems, substance dependence, diversion,
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and low adherence reported suggest that data were not biased
by substantial under-reporting of socially undesirable be-
haviors. This research is also based on cross-sectional data,
which does not allow for the examination of changes over
time. This limits our ability to assess the directionality of
these associations; as such, our data do not provide direct
evidence that reducing stigma would improve ARV adher-
ence or the uptake of HIV care. Nevertheless, these strong
associations suggest that interventions related to stigma may
be useful in promoting more positive health outcomes for
PLWHA. Finally, our measure of HIV stigma only contained
a small number of items and does not take into account the
fact that multiple and layered stigmas are likely interacting
among this sample. Based on the data presented here, we are
unable to consider the interaction of multiple stigmas, given
that the nature of stigma can vary for the same person across
contexts.41 It would be important for future research to ex-
amine how these aspects interact to get a better understanding
of how they may influence PLWHA.13
Conclusions
Although the early management and treatment of HIV has
been shown to reduce disease-related morbidity and improve
long-term health and quality of life,42,43 our findings com-
plement the existing literature indicating that HIV-related
stigma represents a significant barrier for PLWHA in ac-
cessing HIV care and engaging in appropriate disease man-
agement behaviors.44,45 Given that HIV disproportionately
impacts those in poverty and those already marginalized by
minority status, sexual orientation, or substance abuse, stig-
ma is likely experienced on multiple or intersecting levels
related to these challenging life circumstances, coupled with
the diagnosis of HIV/AIDS.2,13,41,46,47 Our findings suggest
that those with substance dependence, depression, and lower
levels of social support are more vulnerable to experiencing
higher levels of HIV-related stigma. These findings have
critical public health implications, including the impor-
tance of developing specifically tailored interventions to
decrease internalized HIV-related stigma, and specifically
self-acceptance stigma. Among PLWHA with high levels
of competing needs, these interventions would appear to
be potential avenues for increasing adherence and routine
utilization of HIV care.
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